US 12,006,325 B2
Substituted furanopyrimidine compounds as PDE1 inhibitors
Brett Bookser, San Diego, CA (US); Iriny Botrous, San Diego, CA (US); Aaron Burns, San Diego, CA (US); DeMichael Chung, San Diego, CA (US); Brian Dyck, San Diego, CA (US); Andrew Kleinke, San Diego, CA (US); Dange Vijay Kumar, San Diego, CA (US); Margaret McCarrick, San Diego, CA (US); Nicholas Raffaele, San Diego, CA (US); Joe Tran, San Marcos, CA (US); and Michael Weinhouse, Lanai City, HI (US)
Assigned to Dart NeuroScience, LLC, Dallas, TX (US)
Filed by Dart NeuroScience, LLC, Dallas, TX (US)
Filed on Sep. 2, 2022, as Appl. No. 17/902,730.
Application 17/902,730 is a continuation of application No. 16/766,258, granted, now 11,434,247, previously published as PCT/US2018/062493, filed on Nov. 26, 2018.
Claims priority of provisional application 62/591,105, filed on Nov. 27, 2017.
Prior Publication US 2023/0295178 A1, Sep. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 491/048 (2006.01); C07D 519/00 (2006.01)
CPC C07D 491/048 (2013.01) [C07D 519/00 (2013.01)] 20 Claims
 
1. A pharmaceutical composition comprising: a pharmaceutically acceptable carrier; and a compound, or a pharmaceutically acceptable salt thereof, selected from group consisting of:
6-methyl-4-[(1-methylcyclopropyl)amino]-N-(1,3-thiazol-4-ylmethyl)furo[2,3-d]pyrimidine-5-carboxamide;
6-methyl-4-[(1-methylcyclopropyl)amino]-N-(1H-pyrrol-2-ylmethyl)furo[2,3-d]pyrimidine-5-carboxamide;
N-[(2-fluorophenyl)methyl]-6-methyl-4-[(1-methylcyclopropyl)amino]furo[2,3-d]pyrimidine-5-carboxamide;
N-[(5-cyclopropyl-1H-pyrazol-3-yl)methyl]-N,6-dimethyl-4-[(1-methylcyclopropyl)amino]furo[2,3-d]pyrimidine-5-carboxamide; and
N-[(6-chloropyridin-3-yl)methyl]-6-methyl-4-[(1-methylcyclopropyl)amino]furo[2,3-d]pyrimidine-5-carboxamide.